Thus, if mitochondria impairment leading to
RPE cell degeneration can be predicted and confined early on, then AMD can be halted or reversed before degeneration spreads.
Not exact matches
For example, a consortium of research groups called the London Project to Cure Blindness aims to test
RPE transplants from embryonic stem
cells in patients with macular
degeneration this year.
«It's fantastic news that they are going into the clinic with a
cell therapy for eye disease,» says Pete Coffey of University College London, and head of a team developing tiny «patches» of
RPEs for treating age - related macular
degeneration.
The researchers detected
RPE cells in the eye of the patient with Stargardt disease but not in the patient with age - related macular
degeneration.
The healthy
RPE cells could also be used in patients at earlier stages of these diseases, to prevent the
degeneration before it starts.
The
degeneration of retinal pigment epithelial (
RPE)
cells as a consequence of impaired mitochondria has emerged as a key feature of early - stage age - related macular
degeneration (AMD).
We further expect our results to show that
RPE cell - secreted vesicles are essential for
cell - to -
cell communication connected to spreading
RPE degeneration in AMD, and therefore, potential therapeutic targets to halt vision loss in AMD.
Our findings open the way to develop therapeutic strategies to remove lipofuscin from
RPE cells, which may have implications for the treatment of age - related macular
degeneration in which lipofuscin accumulation in
cells is a causative factor.
These findings suggest that
RPE cells, derived from iPS
cells, could be used to treat blindness in humans, such as blindness caused by age - related macular
degeneration, a leading cause of blindness in the Western world.
A pilot study assessing the safety and feasibility of the transplantation of autologous iPSC - derived retinal pigment epithelium (
RPE)
cell sheets in patients with exudative (wet - type) age - related macular
degeneration was launched in Japan in August 2013.
Lanza's team figured out how to coax stem
cells taken from human embryos into becoming the
RPE cells that die off along with photoreceptors in macular
degeneration, and in 2011 the team began injecting these manufactured
cells into patients» eyes.
In many forms of human retinal disease, including age - related macular
degeneration (AMD), the underlying pathogenesis resides within the support
cells of the retina, the retinal pigment epithelium (
RPE).
The ensuing dysfunction, distress and sometimes death of the
RPE cells results in age related macular
degeneration.